Exact Sciences Beat Expectations in Q1: Why Investors Didn't Jump for Joy

Exact Sciences (NASDAQ:EXAS) hasn't delivered the sizzling performance so far in 2021 that it did last year. That hasn't stopped Cathie Wood from scooping up more shares of the molecular diagnostics company for her ARK Innovation ETF (NYSEMKT:ARKK).